Gilead Sciences to acquire Repare’s RP-3467
Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467. The transaction involves a…
24 Dec 2025
Zydus and Bioeq partner for commercialisation of Nufymco in US
Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq for the US commercialisation of Vascular Endothelial Growth Factor (VEGF) inhibitor Nufymco, an interchangeable biosimilar…
23 Dec 2025
Ipsen outlays $1bn for China-based Simcere’s preclinical ADC
Ipsen has added a Chinese-developed antibody drug conjugate (ADC) to its pipeline in a deal that could top $1bn, cementing the anti-tumour modality’s status as one of the standout performers…
23 Dec 2025
Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for Lunsumio VELO subcutaneous (SC) formulation to treat adult patients with relapsed…
23 Dec 2025
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
Novo Nordisk has ushered in a new era of obesity treatment – gaining the first US Food and Drug Administration (FDA) approval for a glucagon-like peptide-1 receptor agonist (GLP-1RA) pill…
23 Dec 2025
Samsung Biologics to acquire Human Genome Sciences
Samsung Biologics has entered into a definitive agreement, through its subsidiary Samsung Biologics America, to acquire Human Genome Sciences from GSK as part of its plan to expand manufacturing capabilities…
22 Dec 2025
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push
BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies to its portfolio. Under the terms of the agreement, BioMarin…